Browse Studies — Arctuva

Phase 2

An Open-Label, Randomized, Multiple-Dose, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of CTAP101 Extended-release Capsules in Pediatric Participants <18 Years of Age With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyr…

CKD Stage 3CKD Stage 4Secondary Hyperparathyroidism+1 more

Estimated

~$10 – $8,750

Find your next paid study

REFORM-HF™ Reducing Fluid Overload Using Renal Independent systeM in Heart Failure Patients